PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Per Falk, M.D., Ph.D., as vice president for Clinical, Medical and Regulatory Affairs for North America. Dr. Falk joins the U.S. Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk Inc., the Novo Nordisk U.S. affiliate, and senior vice president for Novo Nordisk A/S, North America.
Dr. Falk brings 23 years of medical, research and pharmaceutical experience to his new position where he will lead clinical research and medical affairs in endocrinology and biopharmaceuticals, as well as regulatory affairs and medical communications.
Dr. Falk joined Novo Nordisk in 2002 as a vice president to establish the Experimental Medicine unit in Denmark. Later he served the company in Tokyo where he was responsible for drug development and market authorization of Novo Nordisk's medical entities in Japan and Australia. In 2008, Dr. Falk transitioned to the United States as the associate vice president of Clinical Development & Medical Affairs - Diabetes & Metabolism where he was responsible for clinical development and medical affairs for all of Novo Nordisk's diabetes and metabolism products, including those in development and on the market.
"As a company, Novo Nordisk has exciting opportunities and ambitious targets in diabetes and biopharmaceuticals with the end goal of improving patients' lives," said Jerzy Gruhn, president of Novo Nordisk Inc. "Dr. Falk is a proven asset to the company and is the ideal leader to help drive the development and marketing of new and lifesaving products to benefit millions of patients across the continent."
Prior to joining Novo Nordisk, Dr. Falk held positions as Director for Gastrointestinal Pharmacology and Molecular Biology in AstraZeneca's CV/GI research unit in Molndal, Sweden. He also has served as a lecturer and associate professor at Karolinska Institute, as well as a post-doctoral fellow and instructor in molecular biology and pharmacology at the Washington University School of Medicine in St. Louis.
Dr. Falk earned his M.D. and Ph.D. from the University of Gothenberg in Sweden. He trained in laboratory medicine at Sahlgren University Hospital and internal medicine/gastroenterology at Karolinska University Hospital.
About Novo Nordisk
Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,550 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
|SOURCE Novo Nordisk|
Copyright©2009 PR Newswire.
All rights reserved